Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation

Jessica Stokes, Emely A. Hoffman, Yi - Zeng, Nicolas Larmonier, Emmanuel Katsanis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b+Gr-1hi cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.

Original languageEnglish (US)
Pages (from-to)102-116
Number of pages15
JournalBritish Journal of Haematology
Volume174
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Experimental Leukemias
Graft vs Host Disease
Bone Marrow Transplantation
Transplants
Cyclophosphamide
Leukemia
Bendamustine Hydrochloride

Keywords

  • bendamustine
  • bone marrow transplantation
  • cyclophosphamide
  • graft-versus-host disease
  • graft-versus-leukaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. / Stokes, Jessica; Hoffman, Emely A.; Zeng, Yi -; Larmonier, Nicolas; Katsanis, Emmanuel.

In: British Journal of Haematology, Vol. 174, No. 1, 01.07.2016, p. 102-116.

Research output: Contribution to journalArticle

@article{15ff389abb414bceac436c653215e728,
title = "Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation",
abstract = "Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b+Gr-1hi cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.",
keywords = "bendamustine, bone marrow transplantation, cyclophosphamide, graft-versus-host disease, graft-versus-leukaemia",
author = "Jessica Stokes and Hoffman, {Emely A.} and Zeng, {Yi -} and Nicolas Larmonier and Emmanuel Katsanis",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/bjh.14034",
language = "English (US)",
volume = "174",
pages = "102--116",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation

AU - Stokes, Jessica

AU - Hoffman, Emely A.

AU - Zeng, Yi -

AU - Larmonier, Nicolas

AU - Katsanis, Emmanuel

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b+Gr-1hi cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.

AB - Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b+Gr-1hi cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT.

KW - bendamustine

KW - bone marrow transplantation

KW - cyclophosphamide

KW - graft-versus-host disease

KW - graft-versus-leukaemia

UR - http://www.scopus.com/inward/record.url?scp=84976486442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976486442&partnerID=8YFLogxK

U2 - 10.1111/bjh.14034

DO - 10.1111/bjh.14034

M3 - Article

C2 - 27030315

AN - SCOPUS:84976486442

VL - 174

SP - 102

EP - 116

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -